Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$5.01 -0.8%	$5.52	$2.68 ▼ $8.22	$157.83M	3.99	286,540 shs	354,006 shs
CNTTF CannTrust		$9.60	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
DMAC DiaMedica Therapeutics	$2.39 -4.0%	$2.83	$1.50 ▼ $4.75	$90.72M	1.69	42,525 shs	21,009 shs
MBRX Moleculin Biotech	$4.65 +2.9%	$7.07	$4.28 ▼ $15.75	$10.37M	1.95	30,571 shs	10,562 shs
SAVA Cassava Sciences	$19.64 -7.3%	$21.72	$12.32 ▼ $32.10	$849.43M	-0.45	771,496 shs	1.31 million shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	-9.01%	-18.94%	-25.63%	+25.31%	+19.39%
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
DMAC DiaMedica Therapeutics	-4.23%	-1.97%	-11.70%	-11.70%	+44.77%
MBRX Moleculin Biotech	+6.07%	-5.02%	-42.22%	-44.66%	-62.17%
SAVA Cassava Sciences	-0.38%	-18.84%	-3.64%	-19.70%	+22.84%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	0.7911 of 5 stars	3.5	0.0	0.0	0.0	1.4	0.8	0.6
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	0.8106 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.0
MBRX Moleculin Biotech	2.278 of 5 stars	3.5	3.0	0.0	0.0	2.9	0.0	1.3
SAVA Cassava Sciences	3.4903 of 5 stars	3.5	1.0	0.0	4.7	3.0	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$24.00	379.04% Upside
CNTTF CannTrust	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	192.89% Upside
MBRX Moleculin Biotech	3.00	Buy	$35.00	652.69% Upside
SAVA Cassava Sciences	3.00	Buy	$124.00	531.36% Upside

Current Analyst Ratings

Latest MBRX, SAVA, CAPR, CNTTF, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	MBRX Moleculin Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/26/2024	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $20.00
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00
3/5/2024	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$124.00
3/1/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$25.18M	6.27	N/A	N/A	$0.73 per share	6.86
CNTTF CannTrust	$15.96M	0.00	N/A	N/A	N/A	NaN
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$0.87	N/A	41.75	N/A	-88.52%	-299.67%	-45.54%	5/9/2024 (Estimated)
CNTTF CannTrust	N/A	$0.07	137.18	0.00	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
MBRX Moleculin Biotech	-$29.77M	-$13.64	N/A	N/A	N/A	N/A	-80.91%	-67.69%	5/9/2024 (Estimated)
SAVA Cassava Sciences	-$97.22M	-$2.32	N/A	11.76	N/A	N/A	-57.53%	-52.58%	5/6/2024 (Estimated)

Latest MBRX, SAVA, CAPR, CNTTF, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
2/29/2024	Q4 2023	CAPR Capricor Therapeutics	-$0.23	-$0.02	+$0.21	-$0.02	$5.80 million	$12.09 million
2/28/2024	Q4 2023	SAVA Cassava Sciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	1.63	1.63
CNTTF CannTrust	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
MBRX Moleculin Biotech	N/A	3.86	3.86
SAVA Cassava Sciences	N/A	9.13	9.13

Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
CNTTF CannTrust	0.08%
DMAC DiaMedica Therapeutics	10.12%
MBRX Moleculin Biotech	15.52%
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	12.00%
CNTTF CannTrust	N/A
DMAC DiaMedica Therapeutics	7.20%
MBRX Moleculin Biotech	6.70%
SAVA Cassava Sciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	31.50 million	27.72 million	Optionable
CNTTF CannTrust	N/A	105.61 million	N/A	Not Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
MBRX Moleculin Biotech	18	2.23 million	2.08 million	Not Optionable
SAVA Cassava Sciences	29	43.25 million	39.35 million	Optionable

MBRX, SAVA, CAPR, CNTTF, and DMAC Headlines

Source	Headline
	Cassava Sciences (NASDAQ:SAVA) Shares Down 6% marketbeat.com - April 19 at 2:56 PM
	Cassava Sciences, Inc. (SAVA) finance.yahoo.com - April 19 at 1:58 PM
	Rail heralded as future for Thai logistics bangkokpost.com - April 17 at 1:27 PM
	Cassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher marketbeat.com - April 16 at 3:43 PM
	Cassava Sciences (NASDAQ:SAVA) Sees Large Volume Increase marketbeat.com - April 15 at 2:49 PM
	Redemption Date Announced for Warrants globenewswire.com - April 15 at 9:20 AM
	Contrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV) americanbankingnews.com - April 15 at 1:44 AM
	Nicklaus: Path to world food security goes through St. Louis stltoday.com - April 14 at 7:17 AM
	Cassava Sciences (NASDAQ:SAVA) Shares Down 9% americanbankingnews.com - April 14 at 4:42 AM
	Cassava Sciences (NASDAQ:SAVA) Trading Down 9% marketbeat.com - April 12 at 2:51 PM
	Vietnam has great potential for biofuel: experts vietnamnet.vn - April 12 at 2:00 PM
	Cassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA) americanbankingnews.com - April 12 at 3:52 AM
	Investors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA) marketbeat.com - April 11 at 4:50 PM
	Cassava Sciences (NASDAQ:SAVA) Sees Strong Trading Volume marketbeat.com - April 9 at 3:19 PM
	Fosukrom farmers trained on organic herbicides, pesticides modernghana.com - April 8 at 8:15 PM
	Zambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Future insideclimatenews.org - April 8 at 8:15 PM
	Cassava Sciences (NASDAQ:SAVA) Trading Up 5.7% marketbeat.com - April 8 at 1:46 PM
	Gates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in Africa agfundernews.com - April 5 at 2:17 AM
	5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Reveals food.ndtv.com - April 5 at 1:13 AM
	Ag nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employees bizjournals.com - April 5 at 1:13 AM
	Strong quake rocks Taiwan, tsunami warnings issued msn.com - April 4 at 4:16 PM
	Can Africa one day help feed the world’s growing population? ft.com - April 3 at 3:22 AM
	Elevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacy myjoyonline.com - April 2 at 5:22 PM
	24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava stockhouse.com - April 2 at 5:22 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Capricor Therapeutics

NASDAQ:CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CannTrust

OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Moleculin Biotech

NASDAQ:MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Cassava Sciences

NASDAQ:SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial